Navigation Links
Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
Date:6/29/2009

Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010

RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being conducted under a Special Protocol Assessment (SPA) with the FDA, has enrolled 260 patients in 13 of the top cancer centers in the US. Yaupon expects the last patient to complete treatment in the study by June of 2010 and, assuming positive results, will file its NDA shortly thereafter.

The randomized, double-blind, controlled clinical study is the largest ever undertaken involving patients with cutaneous T-cell lymphoma. Over one percent (1%) of all people with CTCL in the United States have enrolled in the study. There are approximately 16,000 to 20,000 patients with CTCL in the United States and each year approximately 2,000 people are newly diagnosed with the disease. If approved by FDA, Clearazide would be the first new therapy available for the treatment of early-stage CTCL in almost a decade.

"Cutaneous T-cell lymphoma, like all cancers, is a terrible burden on families worldwide. Completion of patient enrollment in this landmark study is a major milestone in our efforts to advance Clearazide through regulatory approval and to help patients with CTCL. We look forward to completing this study and filing our NDA next year," said Robert J. Alonso, Chief Executive Officer of Yaupon.

Cutaneous T-cell lymphoma is a cancer of the T-lymphocytes in the skin. Early-stage CTCL (stages 1-2a) is the most common presentation of the cancer and affects roughly 67% of the 20,000 patients with the disease. CTCL is a low-grade lymphoma and usually develops very slowly. It
'/>"/>

SOURCE Yaupon Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... trademark owners have been battling search engines and online ... that trigger online advertising. Two recent and conflicting rulings ... law to the new keyword technology can be a ... a recent court ruling on advertising triggered by the ...
... high gas costs and poor sport utility vehicle (SUV) ... at the University of Wisconsin-Madison has spent the last ... fuel-efficient SUVs in North America. The principles behind the ... incorporated into mass-production hybrid SUVs. , ,The effort is ...
... Wis. - Before Gov. Jim Doyle ... of stem cell research, a key Republican legislator had already ... projects. , ,The projects, which now are the subject of ... the Doyle Administration by State Sen. Ted Kanavas , ...
Cached Biology Technology:Keyword advertisers win some, lose some 2Keyword advertisers win some, lose some 3Keyword advertisers win some, lose some 4Keyword advertisers win some, lose some 5UW-Madison hybrid-vehicle team places second nationally 2GOP lawmaker faults Doyle for IT problems 2GOP lawmaker faults Doyle for IT problems 3
(Date:4/14/2014)... RICHLAND, Wash. Think of the pressure change you feel ... tall building. Imagine how you,d feel if that elevator carried ... Everest in the blink of an eye. , That,s ... the turbulent waters near a dam. For some, the change ... die or are seriously injured. , In an article in ...
(Date:4/14/2014)... collaborators have reconstructed the phylogeny and biological history for ... region of the Earth surrounding the equator. In-depth ... species new to science, each having previously been confused ... on this group began, Sturnira has grown ... were described in a new study, published online in ...
(Date:4/14/2014)... an animal stops to look around its environment, neuroscientists ... the birth of a memory. , Using lab ... neuroscience in the Zanvyl Krieger Mind/Brain Institute at Johns ... the rats frequently paused to inspect their environment with ... this behavior activated a place cell in their brain, ...
Breaking Biology News(10 mins):Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5Three new species of yellow-shouldered bats discovered in museum collections 2Three new species of yellow-shouldered bats discovered in museum collections 3Neuroscientists: Brain activity may mark the beginning of memories 2Neuroscientists: Brain activity may mark the beginning of memories 3
... years of exhaustive analysis led by a University of Alberta ... exploded from just a handful to more than 4,000. ... ailing patient looks at something like 10 to 20 chemicals," ... blood chemicals that doctors can potentially look at to diagnose ...
... 24, 2011 For a week in March, the permanent ... and other attractions becomes the world capital of science as ... 241st National Meeting & Exposition of the American Chemical Society ... world,s largest scientific society, and the sessions in balmy Anaheim ...
... identified a strain of probiotic bacteria that may be useful ... They report their findings in the February 2011 issue of ... H. pylori is considered one of the major risk ... ulcers," write the researchers. "Currently, antibiotic-based treatment for ...
Cached Biology News:Researcher lists more than 4,000 components of blood chemistry 2American Chemical Society National Meeting & Exposition, March 27-31, Anaheim, Calif. 2Probiotic identified to treat ulcers 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: